泰格醫藥(03347.HK)2024年淨利同比預降72%-81%
格隆匯1月24日丨泰格醫藥(03347.HK)公吿,2024年度業績預吿,營收人民幣60億元-70億元,比上年同期下降5%-19%;歸屬於上市公司股東的淨利潤人民幣3.8億元–5.7億元,比上年同期下降72%-81%。
經過不懈努力,公司的新簽訂單數量和金額均較去年同期實現較好增長,新簽訂單增長主要來自於大型跨國藥企在國內的需求和中國藥企、生物科技公司以及其合作伙伴和海外早期生物科技公司在海外的臨牀需求增加。報吿期內,公司訂單需求企穩,合同金額同比有所增長,新簽訂單為人民幣95億元至人民幣105億元,受存量訂單(絕大部分為2024年前簽署)取消的影響,淨新增訂單為人民幣84億元至人民幣89億元,2023年淨新增訂單為人民幣78.50億元。
報吿期內公司繼續保持中國臨牀研究外包行業的領先地位,根據中國科學技術部項目數量的數據統計,公司的市場佔有率繼續位列第一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.